Skip to content
Study details
Enrolling now

2'-FL Dietary Supplement Trial for IBD

Children's Hospital Medical Center, Cincinnati
NCT IDNCT03847467ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

116

Study length

about 7.8 years

Ages

11–25

Locations

3 sites in CT, OH

About this study

This trial is testing a dietary supplement called 2'-FL in people with Inflammatory Bowel Diseases (IBD), Crohn's Disease, and Ulcerative Colitis. Participants will receive either 2'-FL or a placebo daily while on stable anti-TNF therapy. The goal is to see if 2'-FL is safe and well-tolerated, and whether it affects the gut microbiome.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take 2'-Fucosyllactose
PhasePhase 1/Phase 2
Primary goalMean Gastrointestinal Symptom Rating Scale (GSRS) in participants who receive 2'-fucosyllactose (2'FL) or dextrose placebo

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Mean Gastrointestinal Symptom Rating Scale (GSRS) in participants who receive 2'-fucosyllactose (2'FL) or dextrose placebo

Body systems

Gastroenterology